Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer
Authors:
- Mahmoud AbdallahMAMahmoud Abdallah
- Rick VolandRVRick Voland
- Malcolm DecampMalcolm Decamp
- John FlickingerJFJohn Flickinger
- Toni PaciolesTPToni Pacioles
- Muhammad JamilMJMuhammad Jamil
- Damian SilberminsDSDamian Silbermins
- Mina ShenoudaMSMina Shenouda
- Matias ValsecchiMVMatias Valsecchi
- Arvinder BirABArvinder Bir
- Yousef ShweihatYSYousef Shweihat
- Juan BastidasJBJuan Bastidas
Open Access
Abstract
Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of immunotherapy. We also review all the past literature and discuss strategies of combining anti-angiogenic therapy and immunotherapy +/− chemotherapy and hypothesize how we can use this strategy for non-small-cell lung cancer in metastatic previously untreated/previously treated settings in previously treated EGFR-mutated NSCLC for the upfront treatment of brain metastases prior to radiation therapy and for the incorporation of this strategy into stage III unresectable disease. We assert the use of anti-angiogenic therapy and immunotherapy when combined appropriately with chemotherapy and radiotherapy has the potential to increase the long-term survivals in both the stage III and metastatic setting so that we can now consider more patients to experience curative treatment.Keywords
This publication has 105 references indexed in Scilit:
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR VariantJAMA, 2024
- Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerAnnals of Oncology, 2021
- Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic RadiationJAMA Oncology, 2018
- Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanomaJournal of Neuro-Oncology, 2017
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain MetastasesJAMA, 2016
- Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastasesSupportive Care in Cancer, 2010
- Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin2010
- Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesJAMA, 2006
- Differential regulation of VEGF, HIF1α and angiopoietin‐1, ‐2 and ‐4 by hypoxia and ionizing radiation in human glioblastomaInternational Journal of Cancer, 2003
- A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994